[Federal Register Volume 70, Number 70 (Wednesday, April 13, 2005)]
[Notices]
[Pages 19446-19452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-7223]


-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[OPP-2005-0047; FRL-7699-9]


Etoxazole; Notice of Filing a Pesticide Petition to Establish a 
Tolerance for a Certain Pesticide Chemical in or on Food

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY:  This notice announces the initial filing of a pesticide 
petition proposing the establishment of regulations for residues of a 
certain pesticide chemical in or on various food commodities.

DATES: Comments, identified by docket identification (ID) number OPP-
2005-0047, must be received on or before May 13, 2005.

ADDRESSES:  Comments may be submitted electronically, by mail, or 
through hand delivery/courier. Follow the detailed instructions as 
provided in Unit I. of the SUPPLEMENTARY INFORMATION.

FOR FURTHER INFORMATION CONTACT:  Kable Bo Davis, Registration Division 
(7505C), Office of Pesticide Programs, Environmental Protection Agency, 
1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone 
number: (703) 306-0415; e-mail address: [email protected].

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

     You may be potentially affected by this action if you an 
agricultural producer, food manufacturer, or pesticide manufacturer. 
Potentially affected entities may include, but are not limited to:
     Crop production (NAICS 111)
     Animal production (NAICS 112)
     Food manufacturing (NAICS 311)
     Pesticide manufacturing (NAICS 32532)
     This listing is not intended to be exhaustive, but rather provides 
a guide for readers regarding entities likely to be affected by this 
action. Other types of entities not listed in this unit could also be 
affected. The North American Industrial Classification System (NAICS) 
codes have been provided to assist you and others in determining 
whether this action might apply to certain entities. If you have any 
questions regarding the applicability of this action to a particular 
entity, consult the person listed under FOR FURTHER INFORMATION 
CONTACT.

B. How Can I Get Copies of this Document and Other Related Information?

    1. Docket. EPA has established an official public docket for this 
action under docket ID number OPP-2005-0047. The official public docket 
consists of the documents specifically referenced in this action, any 
public comments received, and other information related to this action. 
Although, a part of the official docket, the public docket does not 
include Confidential Business Information (CBI) or other information 
whose disclosure is restricted by statute. The official public docket 
is the collection of materials that is available for public viewing at 
the Public Information and Records Integrity Branch (PIRIB), Rm. 119, 
Crystal Mall 2, 1801 S. Bell St., Arlington, VA. This docket 
facility is open from 8:30 a.m. to 4 p.m., Monday through Friday, 
excluding legal holidays. The docket telephone number is (703) 305-
5805.
    2. Electronic access. You may access this Federal Register document 
electronically through the EPA Internet under the ``Federal Register'' 
listings at http://www.epa.gov/fedrgstr/.
     An electronic version of the public docket is available through 
EPA's electronic public docket and comment system, EPA Dockets. You may 
use EPA Dockets at http://www.epa.gov/edocket/ to submit or view public 
comments, access the index listing of the contents of the official 
public docket, and to access those documents in the public docket that 
are available electronically. Although, not all docket materials may be 
available electronically, you may still access any of the publicly 
available docket materials through the docket facility identified in 
Unit I.B.1. Once in the system, select ``search,'' then key in the 
appropriate docket ID number.
     Certain types of information will not be placed in the EPA 
Dockets. Information claimed as CBI and other information whose 
disclosure is restricted by statute, which is not included in the 
official public docket, will not be available for public viewing in 
EPA's electronic public docket. EPA's policy is that copyrighted 
material will not be placed in EPA's electronic public docket but will 
be available only in printed, paper form in the official public docket. 
To the extent feasible, publicly available docket materials will be 
made available in EPA's electronic public docket. When a document is 
selected from the index list in EPA Dockets, the system will identify 
whether the document is available for viewing in EPA's electronic 
public docket. Although, not all docket materials may

[[Page 19447]]

be available electronically, you may still access any of the publicly 
available docket materials through the docket facility identified in 
Unit I.B. EPA intends to work towards providing electronic access to 
all of the publicly available docket materials through EPA's electronic 
public docket.
     For public commenters, it is important to note that EPA's policy 
is that public comments, whether submitted electronically or on paper, 
will be made available for public viewing in EPA's electronic public 
docket as EPA receives them and without change, unless the comment 
contains copyrighted material, CBI, or other information whose 
disclosure is restricted by statute. When EPA identifies a comment 
containing copyrighted material, EPA will provide a reference to that 
material in the version of the comment that is placed in EPA's 
electronic public docket. The entire printed comment, including the 
copyrighted material, will be available in the public docket.
     Public comments submitted on computer disks that are mailed or 
delivered to the docket will be transferred to EPA's electronic public 
docket. Public comments that are mailed or delivered to the docket will 
be scanned and placed in EPA's electronic public docket. Where 
practical, physical objects will be photographed, and the photograph 
will be placed in EPA's electronic public docket along with a brief 
description written by the docket staff.

C. How and to Whom Do I Submit Comments?

     You may submit comments electronically, by mail, or through hand 
delivery/courier. To ensure proper receipt by EPA, identify the 
appropriate docket ID number in the subject line on the first page of 
your comment. Please ensure that your comments are submitted within the 
specified comment period. Comments received after the close of the 
comment period will be marked ``late.'' EPA is not required to consider 
these late comments. If you wish to submit CBI or information that is 
otherwise protected by statute, please follow the instructions in Unit 
I.D. Do not use EPA Dockets or e-mail to submit CBI or information 
protected by statute.
    1. Electronically. If you submit an electronic comment as 
prescribed in this unit, EPA recommends that you include your name, 
mailing address, and an e-mail address or other contact information in 
the body of your comment. Also, include this contact information on the 
outside of any disk or CD ROM you submit, and in any cover letter 
accompanying the disk or CD ROM. This ensures that you can be 
identified as the submitter of the comment and allows EPA to contact 
you in case EPA cannot read your comment due to technical difficulties 
or needs further information on the substance of your comment. EPA's 
policy is that EPA will not edit your comment, and any identifying or 
contact information provided in the body of a comment will be included 
as part of the comment that is placed in the official public docket, 
and made available in EPA's electronic public docket. If EPA cannot 
read your comment due to technical difficulties and cannot contact you 
for clarification, EPA may not be able to consider your comment.
    i. EPA Dockets. Your use of EPA's electronic public docket to 
submit comments to EPA electronically is EPA's preferred method for 
receiving comments. Go directly to EPA Dockets at http://www.epa.gov/edocket/, and follow the online instructions for submitting comments. 
Once in the system, select ``search,'' and then key in docket ID number 
OPP-2005-0047. The system is an ``anonymous access'' system, which 
means EPA will not know your identity, e-mail address, or other contact 
information unless you provide it in the body of your comment.
    ii. E-mail. Comments may be sent by e-mail to [email protected], 
Attention: Docket ID number OPP-2005-0047. In contrast to EPA's 
electronic public docket, EPA's e-mail system is not an ``anonymous 
access'' system. If you send an e-mail comment directly to the docket 
without going through EPA's electronic public docket, EPA's e-mail 
system automatically captures your e-mail address. E-mail addresses 
that are automatically captured by EPA's e-mail system are included as 
part of the comment that is placed in the official public docket, and 
made available in EPA's electronic public docket.
    iii. Disk or CD ROM. You may submit comments on a disk or CD ROM 
that you mail to the mailing address identified in Unit I.C.2. These 
electronic submissions will be accepted in WordPerfect or ASCII file 
format. Avoid the use of special characters and any form of encryption.
    2. By mail. Send your comments to: Public Information and Records 
Integrity Branch (PIRIB) (7502C), Office of Pesticide Programs (OPP), 
Environmental Protection Agency, 1200 Pennsylvania Ave., NW., 
Washington, DC 20460-0001, Attention: Docket ID number OPP-2005-0047.
    3. By hand delivery or courier. Deliver your comments to: Public 
Information and Records Integrity Branch (PIRIB), Office of Pesticide 
Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall 
2, 1801 S. Bell St., Arlington, VA, Attention: Docket ID 
number OPP-2005-0047. Such deliveries are only accepted during the 
docket's normal hours of operation as identified in Unit I.B.1.

D. How Should I Submit CBI to the Agency?

     Do not submit information that you consider to be CBI 
electronically through EPA's electronic public docket or by e-mail. You 
may claim information that you submit to EPA as CBI by marking any part 
or all of that information as CBI (if you submit CBI on disk or CD ROM, 
mark the outside of the disk or CD ROM as CBI and then identify 
electronically within the disk or CD ROM the specific information that 
is CBI). Information so marked will not be disclosed except in 
accordance with procedures set forth in 40 CFR part 2.
     In addition to one complete version of the comment that includes 
any information claimed as CBI, a copy of the comment that does not 
contain the information claimed as CBI must be submitted for inclusion 
in the public docket and EPA's electronic public docket. If you submit 
the copy that does not contain CBI on disk or CD ROM, mark the outside 
of the disk or CD ROM clearly that it does not contain CBI. Information 
not marked as CBI will be included in the public docket and EPA's 
electronic public docket without prior notice. If you have any 
questions about CBI or the procedures for claiming CBI, please consult 
the person listed under FOR FURTHER INFORMATION CONTACT.

E. What Should I Consider as I Prepare My Comments for EPA?

     You may find the following suggestions helpful for preparing your 
comments:
    1. Explain your views as clearly as possible.
    2. Describe any assumptions that you used.
    3. Provide copies of any technical information and/or data you used 
that support your views.
    4. If you estimate potential burden or costs, explain how you 
arrived at the estimate that you provide.
    5. Provide specific examples to illustrate your concerns.
    6. Make sure to submit your comments by the deadline in this 
notice.
    7. To ensure proper receipt by EPA, be sure to identify the docket 
ID number assigned to this action in the subject line on the first page 
of your response.

[[Page 19448]]

You may also provide the name, date, and Federal Register citation.

II. What Action is the Agency Taking?

     EPA has received a pesticide petition as follows proposing the 
establishment and/or amendment of regulations for residues of a certain 
pesticide chemical in or on various food commodities under section 408 
of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a. 
EPA has determined that this petition contains data or information 
regarding the elements set forth in FFDCA section 408(d)(2); however, 
EPA has not fully evaluated the sufficiency of the submitted data at 
this time or whether the data support granting of the petition. 
Additional data may be needed before EPA rules on the petition.

List of Subjects

     Environmental protection, Agricultural commodities, Feed 
additives, Food additives, Pesticides and pests, Reporting and 
recordkeeping requirements.

    Dated: April 1, 2005.
Lois Rossi,
Director, Registration Division, Office of PesticidePrograms.

Summary of Petition

     The petitioner's summary of the pesticide petition is printed 
below as required by FFDCA section 408(d)(3). The summary of the 
petition was prepared by Valent U.S.A. Corporation and represents the 
view of the petitioner. The petition summary announces the availability 
of a description of the analytical methods available to EPA for the 
detection and measurement of the pesticide chemical residues or an 
explanation of why no such method is needed.

 Valent U.S.A. Corporation

 PP 3F6739

     EPA has received a pesticide petition PP 3F6739 from Valent U.S.A. 
Corporation, 1333 North California Boulevard, Suite 600, Walnut Creek, 
CA 94596-8025 proposing, pursuant to section 408(d) of the Federal 
Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a(d), to amend 40 
CFR part 180, by establishing a tolerance for residues of the chemical 
etoxazole, 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-
ethoxyphenyl]-4,5-dihydrooxazole, in or on the raw agricultural 
commodities nut, tree (Crop Group 14), including pistachios at 0.01 
parts per million (ppm), almond, hulls at 2.0 ppm, grapes at 0.5 ppm, 
and raisins at 1.5 ppm. EPA has determined that the petition contains 
data or information regarding the elements set forth in section 
408(d)(2) of the FFDCA; however, EPA has not fully evaluated the 
sufficiency of the submitted data at this time or whether the data 
support granting of the petition. Additional data may be needed before 
EPA rules on the petition.

A. Residue Chemistry

    1. Plant metabolism. The metabolism of etoxazole is adequately 
understood for the purpose of the proposed tolerances.
    2. Analytical methods. Practical analytical methods for detecting 
and measuring levels of etoxazole have been developed and validated in/
on all appropriate agricultural commodities and respective processing 
fractions. The extraction methodology has been validated using aged 
radiochemical residue samples from 14C-metabolism studies. 
The enforcement methods have been validated in cottonseed, cotton gin 
trash, and in fresh mandarin oranges at independent laboratories. The 
LOQ of etoxazole in these methods is 0.01 ppm in grapes and nutmeats 
and 0.05 ppm in almond, hulls, which will allow monitoring of food with 
residues at the levels proposed for the tolerances.
    3. Magnitude of residues. An extensive crop residue program has 
been conducted for etoxazole in all major growing regions of the United 
States for the following crops: Almond and pecans (representing nut, 
tree, Crop Group 14), and grapes. The results of these studies can be 
summarized as follows:
     For almonds, the maximum etoxazole residues from two 
applications at 0.135 pounds active ingredient/acre/treatment, was 
0.005 ppm for nutmeats and 1.79 ppm for hulls harvested 28-days after 
application. Almond hulls were also analyzed for R-3, a metabolite of 
etoxazole. The maximum residue of R-3 was as 0.12 ppm.
     For pecans, no etoxazole residues were observed in 
nutmeats (LOD = 0.005 ppm) treated twice at 0.135 pounds active 
ingredient/acre/treatment and harvested 28-days after application.
     The maximum etoxazole residue in grapes harvested 28-days 
following the last of two treatments at 0.135 pounds active ingredient/
acre/treatment was 0.33 ppm.
     The results of a grape processing study indicate that 
etoxazole residues concentrate in both grape juice and raisins. The 
concentration factor for grape juice was determined in this study to be 
5.3X, which exceeds the theoretical concentration factor of 1.2X. Using 
this theoretical concentration factor to estimate the tolerance for 
juice, a tolerance of 0.32 ppm was calculated. Since this tolerance is 
less than the tolerance proposed for grapes, grape juice tolerances are 
not required. The concentration factor for raisins was determined in 
this study to be 3.5X. The theoretical concentration factor for raisins 
is, however, 4.7x. To be consistent with the grape juice calculations, 
this theoretical concentration factor was used to determine the 
proposed tolerance for raisins.
     These field trial data are adequate to support proposed tolerances 
of 0.01 ppm for nut, tree (Crop Group 14); pistachios at 0.01 ppm; 2.0 
ppm for almond, hull; 0.5 ppm for grapes; and 1.5 ppm for raisins.
     Almond, hull is the only commodity under consideration that is a 
significant feed item for beef and dairy cattle. Tolerances of 0.03 ppm 
in the fat of animals and 0.04 ppm in milk fat, previously proposed and 
pending at the Agency, are adequate to support the use on almonds.
     None of the commodities under consideration are used as poultry 
feed items. Additionally, the results of a hen metabolism study 
demonstrated very low potential for residues in feed to transfer to 
poultry tissues or eggs. Therefore, no hen residue feeding study was 
performed and tolerances are not proposed for secondary residues in 
poultry commodities.

B. Toxicological Profile

     A full battery of toxicology testing, including studies of acute, 
chronic, oncogenicity, developmental, mutagenicity, and reproductive 
effects has been completed for etoxazole. The acute toxicity of 
etoxazole is low by all routes. Etoxazole is not a developmental or 
reproductive toxicant, and is not mutagenic or oncogenic. For the 
purpose of dietary risk analysis, Valent proposes 0.04 milligrams/
kilogram body weight/day (mg/kg bwt/day) as the chronic Population 
Adjusted Dose (cPAD) and 2 mg/kg bwt/day as the acute Population 
Adjusted Dose (aPAD). The cPAD is based on a chronic endpoint of 4 mg/
kg bwt/day no observed adverse effect level (NOAEL) for males from the 
rat chronic/oncogenicity feeding study and an uncertainty factor of 
100. The aPAD is based on the 200 mg/kg bwt/day NOAEL from the rabbit 
developmental toxicity study and an uncertainty factor of 100. Valent 
is unable to identify toxicity endpoints of concern for acute, short-
term or chronic human exposures by any route other than oral.

[[Page 19449]]

    1. Acute toxicity. The acute toxicity of technical grade etoxazole 
is low by all routes. The battery of acute toxicity studies place 
etoxazole in Toxicity Category III. The oral LD50 in the rat 
was greater than 5 grams/kilogram (g/kg), the dermal LD50 
was greater than 2.0 g/kg, and the inhalation LC50 in the 
rat was greater than 1.09 milligrams/liter (mg/L). Etoxazole technical 
was not an irritant to eyes or skin and was not a skin sensitizer.
    2. Genotoxicity. Etoxazole was evaluated and found to be negative 
in an Ames reverse mutation assay, a chromosome aberration assay, a 
micronucleus assay, and an unscheduled DNA synthesis (UDS) assay. 
Etoxazole produced a positive result in the mouse lymphoma gene 
mutation assay but only in the presence of metabolic activation. 
Etoxazole does not present a genetic hazard.
    3. Reproductive and developmental toxicity--i. Rat developmental 
study. Etoxazole did not produce developmental toxicity in rats. 
Etoxazole technical was administered by oral gavage to pregnant rats at 
dosage levels of 40, 200, and 1,000 mg/kg/day on days 6 through 15 of 
gestation. There were no mortalities or treatment-related adverse 
effects in any dose group. Food consumption was slightly decreased in 
dams during the dosing period for the 1,000 mg/kg/day group. On 
cesarean section evaluation there was no differences in number of 
corpora lutea, number of live and dead fetuses, percent resorption, 
placental weight, fetal weight or sex ratio in the dams and no 
treatment-related external, visceral or skeletal malformations noted in 
any of the fetuses. It was concluded that, the maternal no observed 
adverse effect Level (NOAEL) was 200 mg/kg/day, based on decreased food 
consumption at 1,000 mg/kg/day. The developmental NOAEL was 1,000 mg/
kg/day, the highest dose tested (HDT).
    ii. Rabbit developmental study. Etoxazole did not produce 
developmental toxicity in rabbits. Etoxazole technical was administered 
by oral gavage to pregnant rabbits at dosage levels of 40, 200, and 
1,000 mg/kg/day on days 6 through 18 of gestation. No treatment-related 
adverse effects were found on maternal rabbits in the 40 and 200 mg/kg/
day groups. One high dose rabbit died but it is unclear whether this 
death was attributed to treatment. Decreased body weight, body weight 
gain, food consumption and enlarged liver were noted at 1,000 mg/kg/
day. Cesarean section findings showed that there was no differences in 
number of corpora lutea, number of live and dead fetuses, percent 
resorptions, placental weight, fetal weight and sex ratio in the dams 
and showed no treatment-related malformations (external, visceral, 
skeletal) in any of the fetuses. A statistically significant increased 
incidence of 27 presacral vertebrae with 13th ribs was 
observed in fetuses at 1,000 mg/kg/day compared with controls. This 
finding was within historical control range for fetal incidence but 
above the historical control range for litter incidence. No dose 
response was evident and the variation is considered to be equivocally 
treatment related. The NOAEL for maternal and developmental toxicity 
was 200 mg/kg/day based on decreased body weight and body weight gain, 
decreased food consumption, and liver enlargement at 1,000 mg/kg/day. 
The NOAEL for developmental toxicity was 200 mg/kg/day based on 
statistically significant increased incidence of 27 presacral vertebrae 
with 13th ribs in fetuses at 1,000 mg/kg/day.
    iii. Rat reproduction study. Etoxazole showed no effects on 
reproduction in a two-generation rat study. Etoxazole technical was fed 
to two generations of male and female Sprague Dawley rats at dietary 
concentrations of 80, 400, and 2,000 ppm. No treatment-related adverse 
effects were observed in the 80 and 400 ppm groups for any parameter. 
In the 2,000 ppm group, relative liver weights were increased in the F0 
and F1 parental males. No adverse reproductive effects were noted at 
any dose level in the incidence of normal estrous cycle, mating index, 
fertility and gestation indices, the number of implantation sites, and 
duration of gestation in F0 and F1 parental animals. For the offspring, 
it was noted that at 2,000 ppm, the viability index on lactation Day 4 
was significantly lower in the F1 pups and body weights were lowered in 
pups during the latter half of the lactation period. For the F0 and F1 
pups of the 80 and 400 ppm groups, there were no treatment-related 
adverse effects observed for any parameter, i.e. mean number of pups 
delivered, sex ratio, viability indices on lactation days 0, 4 and 21, 
clinical signs, body weights and gross pathological findings. The 
parental NOAEL was 400 ppm (17.0 mg/kg/day) based on the effects on 
relative liver weight in males at 2,000 ppm. The pup NOAEL was 400 ppm 
(37.9 mg/kg/day) based on decreased viability on lactation Day 4 and 
decreased body weight at 2,000 ppm in the F1 pups. The reproductive 
NOAEL was 2,000 ppm (86.4 mg/kg/day), the (HDT).
    4. Subchronic toxicity. Subchronic toxicity studies conducted with 
etoxazole technical in the rat (oral and dermal), mouse and dog 
indicate a low level of toxicity. Effects observed at high dose levels 
consisted primarily of anemia and histological changes in the adrenal 
gland, liver and kidneys.
    i. Rat feeding study. A 90-day subchronic toxicity study was 
conducted in rats, with dietary intake levels of 100, 300, 1,000 and 
3,000 ppm etoxazole technical. The NOAEL was 100 ppm for males and 300 
ppm for females based on increased incidence of hepatocellular swelling 
at 1,000 ppm and 3,000 ppm.
    ii. Mouse feeding study. A 90-day subchronic toxicity study was 
conducted in mice, with dietary intake levels of 100, 400, 1,600, and 
6,400 ppm etoxazole technical. The NOAEL was 400 ppm for males and 
1,600 ppm for females based on increased alkaline phosphatase activity, 
increased liver weights, and increased incidence of hepatocellular 
swelling at 6,400 ppm (both sexes) and at 1,600 ppm in males and 
enlarged livers in females at 6,400 ppm.
    iii. Dog feeding study. Etoxazole technical was fed to male and 
female Beagle dogs for 13 weeks at dietary concentrations of 200, 
2,000, and 10,000 ppm. The NOAEL was 200 ppm (5.3 mg/kg/day) based on 
clinical signs, clinical pathology changes, liver weight effects and 
histopathological changes at 2,000 and 10,000 ppm.
    iv. Repeated dose dermal study. A 28-day dermal toxicity study was 
conducted in rats at dose levels of 30, 100, and 1,000 mg/kg. There 
were no treatment related changes in any of the parameters monitored. 
The NOAEL was 1,000 mg/kg, the (HDT).
    5. Chronic toxicity. Etoxazole technical has been tested in chronic 
studies with dogs, rats and mice. Valent proposes a chronic oral 
endpoint of 4 mg/kg bwt/day, based on the NOAEL for male rats in a 2-
year chronic toxicity oncogenicity feeding study.
    i. Dog chronic feeding study. Etoxazole technical was fed to male 
and female beagle dogs for one year at dietary concentrations of 200, 
1,000, and 5,000 ppm. The NOAEL was 200 ppm (4.6 mg/kg/day for males 
and 4.79 mg/kg/day for females) based on increased absolute and 
relative liver weights with corresponding histopathological changes in 
the liver at 1,000 and 5,000 ppm.
    ii. Rat chronic feeding/oncogenicity study. Etoxazole was not 
oncogenic in rats in either of two chronic feeding studies conducted. 
In the first study, etoxazole technical was fed to male and female 
Sprague Dawley rats for 2-years at dietary concentrations of 4, 16, and 
64 mg/kg/day. A trend toward decreased

[[Page 19450]]

body weight gain for males at 64 mg/kg/day in the latter half of the 
study was observed. Hemotology and clinical chemistry changes, 
increased liver weights and hepatic enlargement at 16 mg/kg/day or 
above were observed. Testicular masses, centrilobular hepatocellular 
swelling and testicular interstitial (Leydig) cell tumors occurred at 
or above 16 mg/kg/day. The interstitial (Leydig) cell tumors were 
believed to be incidental. The NOAEL was 4 mg/kg/day for males and 16 
mg/kg/day for females. Because an MTD level was not achieved in this 
study, a second study was conducted in which etoxazole technical was 
fed to male and female Sprague Dawley rats for 2-years at dietary 
concentrations of 50, 5,000, and 10,000 ppm. In this study, decreased 
mortality, body weight and food consumption/ efficiency (females) at 
10,000 ppm was observed. Hematological, clinical, and histopathological 
changes of the incisors, and increased liver weights occurred in both 
sexes at 5,000 and 10,000 ppm. Centrilobular hepatocellular hypertrophy 
was observed in both sexes at 10,000 ppm. The interstitial (Leydig) 
cell tumors observed in the first study, were not observed in the 
repeat study. The NOAEL in the repeat study was 50 ppm (1.8 mg/kg/day).
    iii. Mouse oncogenicity study. Etoxazole was not oncogenic in 
either of 2 mouse oncogenicity studies conducted. In the first study, 
etoxazole technical was fed to male and female CD-1 mice for 18-months 
at dietary concentrations of 15, 60, and 240 mg/kg/day. Increased liver 
weights occurred in females at the highest dose tested. Histopathology 
parameters were altered for males at 240 mg/kg/day. No neoplastic 
lesions were observed at any dose level. The NOAEL was 60 mg/kg/day. 
Since the toxicity in this study was minimal and did not meet the 
definition of MTD, a second study was conducted at dose levels of 2,250 
and 4,500 ppm etoxazole. There were no effects in any group on clinical 
observations, mortality, body weight, food consumption or hematology. 
Females showed a significant elevation in relative liver weight after 
52-weeks of treatment at 4,500 ppm. In histopathology, a significantly 
higher incidence of centrilobular hepatocellular fatty change was 
observed in males in the 4,500 ppm group necropsied after 78-weeks of 
treatment. There were no treatment-related changes in either sex in the 
2,250 ppm dose group. No increase in neoplastic lesions were observed 
in any treated group of either sex. Therefore, it was concluded that, 
the NOAEL is 2,250 ppm (242 mg/kg/day for the males and 243 mg/kg/day 
for the females).
    6. Animal metabolism. The absorption, tissue distribution, 
metabolism and excretion of etoxazole were studied in rats after single 
oral doses of 5 or 500 mg/kg, and after 14 daily oral doses at 5 mg/kg. 
Etoxazole, labeled in both the t-butylphenyl ring and the oxazole ring 
were used in this study. For both single dose groups, most (94-97%) of 
the administered radiolabel was excreted in the urine and feces within 
7-days after dosing. Most of this excretion occurred in the first 48 
hours after dosing. Maximum plasma concentrations occurred 2-4 hours 
after dosing, with half-lives ranging from 53-89 hours at the low dose 
and 7-44 hours at the high dose. Plasma levels were significantly lower 
in females. Concentrations of radioactivity were significantly higher 
in the tissues of male rats compared to females. The highest 
concentrations occurred at 3 hours after dosing and were greatest in 
the gastrointestinal tract and tissues such as liver and kidneys, which 
are responsible for metabolism and excretion. By 168 hours, the 
concentration in most tissues was below the concentration in the 
corresponding plasma, with only the liver and fat having significant 
levels of radioactivity. After multiple doses, peak concentrations of 
radioactivity in tissues occurred 2 hours after dosing and then 
declined. The distribution of radioactivity showed a similar profile to 
those found after single oral doses but were significantly higher, 
indicating some accumulation. Etoxazole was extensively metabolized by 
rats. The main metabolic reactions in rats were postulated to be 
hydroxylation of the 4,5-hydrooxazole ring followed by cleavage of the 
molecule and hydroxylation of the t-butyl side chain.
    7. Metabolite toxicology. In an oral toxicity limit test in rats, 
the oral LD50 of metabolite R-3 was estimated to be greater 
than 5 g/kg for both male and female rats. No treatment related body 
weight changes and no treatment related macroscopic abnormalities were 
observed in this study. In another test, the oral toxicity of 
metabolite R-7 (as the HCl salt) was assessed. The oral LD50 
of this metabolite was also estimated to be greater than 5 g/kg for 
both male and female rats. No treatment related macroscopic 
abnormalities were observed in this test, although, some clinical signs 
were observed within 6-minutes of dosing. Mutagenicity screens were 
performed with metabolite R-3 and metabolite R-7 (as the HCl salt). 
Neither metabolite was mutagenic when tested with multiple strains of 
two bacterial cultures (salmonella typhimurium and e coli).
    8. Endocrine disruption. No special studies to investigate the 
potential for estrogenic or other endocrine effects of etoxazole have 
been performed. However, as summarized above, a large and detailed 
toxicology data base exists for the compound including studies in all 
required categories. These studies include acute, sub-chronic, chronic, 
developmental, and reproductive toxicology studies including detailed 
histology and histopathology of numerous tissues, including endocrine 
organs, following repeated or long term exposures. These studies are 
considered capable of revealing endocrine effects. The results of all 
of these studies show no evidence of any endocrine-mediated effects and 
no pathology of the endocrine organs. Consequently, it is concluded 
that etoxazole does not possess estrogenic or endocrine disrupting 
properties.

C. Aggregate Exposure

    1. Dietary exposure. A full battery of toxicology testing including 
studies of acute, chronic, oncogenicity, developmental, mutagenicity, 
and reproductive effects is available for etoxazole. In these risk 
assessments, Valent proposes as the chronic oral toxic endpoint the 
NOAEL for males from the rat chronic/oncogenicity feeding study, 4 mg/
kg/day. To assess the chronic risk to the U.S. population from exposure 
to etoxazole, the daily chronic exposures were compared against an 
estimated chronic population adjusted dose (cPAD) of 0.04 mg/kg bwt/
day. This endpoint is derived from the NOAEL from the 2-year chronic 
rat study by applying an uncertainty factor of 100 to account for 
intraspecies and interspecies variations. There is no evidence that any 
additional safety factors are needed to further protect vulnerable 
subpopulations. The proposed acute oral toxic endpoint is the NOAEL 
from the rabbit oral developmental toxicity study, 200 mg/kg/day. To 
assess the acute risk to the U.S. population from exposure to 
etoxazole, acute exposures were compared against an estimated acute 
population adjusted dose (aPAD) of 2 mg/kg bwt/day. This endpoint is 
derived from the NOAEL from the rabbit oral developmental toxicity 
study by applying an uncertainty factor of 100 to account for 
intraspecies and interspecies variations. Based on dietary, drinking 
water, and non-occupational exposure assessments, there is reasonable 
certainty of no harm

[[Page 19451]]

to the U.S. population, any population subgroup, or infants and 
children from short-term or chronic exposure to etoxazole.
    i. Food. Dietary exposure was estimated using the Cumulative and 
Aggregate Risk Evaluation System (CARES). Acute dietary exposure was 
estimated for the overall U.S. population and 16 population subgroups 
using proposed tolerances and conservative estimates of the percentages 
of crop treated. The results demonstrate that estimated exposure is 
less than 1% of the estimated aPAD (at the 99.9th 
percentile) for all population groups examined. Acute dietary exposure 
for the overall U.S. population was estimated to be 0.006 mg/kg bwt/day 
at the 99.9th percentile of exposure (0.29% of the aPAD). 
Chronic dietary exposure was estimated for the overall U.S. population 
and 16 population subgroups. Annual exposure for the overall U.S. 
population was estimated to be 0.00014 mg/kg bwt/day, representing 
0.36% of the estimated cPAD. Annual exposure for the most highly 
exposed population subgroup, children 1-2 years of age, was estimated 
to be 0.00065 mg/kg bwt/day, or 1.62% of the estimated cPAD.
    ii. Drinking water. Since etoxazole is applied outdoors to growing 
agricultural crops, the potential exists for the parent or its 
metabolites to reach ground water or surface water that may be used for 
drinking water. But, because of the physical properties of etoxazole, 
it is unlikely that etoxazole or its metabolites can leach to potable 
ground water. Although, relatively stable to hydrolysis, etoxazole 
undergoes fairly rapid photolysis, degrades fairly readily in soil and 
is immobile in all soil types examined. To quantify potential exposure 
from drinking water, FIRST and SCI-GROW models were used to estimate 
surface water and ground water residues. Estimated surface water 
residues were much higher than estimated ground water residues and 
therefore, the surface residues were used as the Drinking Water 
Environmental Concentration (DWEC). The peak (acute) concentration 
predicted in the simulated pond water was estimated to be 2.47 ppb and 
the annual average (chronic) concentration predicted in the simulated 
pond water was estimated to be 1.93 ppb. To assess the contribution to 
the dietary risk from exposure to drinking water containing residues of 
etoxazole, these DWEC's are compared to drinking water levels of 
comparison (DWLOC's), the maximum drinking water concentration allowed 
before combined water, dietary, and other exposures will exceed the 
population adjusted doses. If the DWLOC is greater than the DWEC, then 
overall exposure will not exceed the population adjusted doses and 
combined exposure from water and food is considered to be acceptable. 
Acute DWLOC's for etoxazole range from 19,900 to 69,910 ppb and chronic 
DWLOC's range from 377 to 1,380 ppb for all U.S. population subgroups 
examined. Since these DWLOC's exceed the modeled acute and chronic DWEC 
surface water residues by a wide margin, it can be concluded that, 
exposure to potential residues in drinking water is negligible and that 
aggregate (food and water) exposure to etoxazole residues will be 
acceptable.
    2. Non-dietary exposure. Etoxazole is proposed only for 
agricultural uses and no homeowner or turf uses. Thus, no non-dietary 
risk assessment is needed.

D. Cumulative Effects

     Section 408(b)(2)(D)(v) requires that the Agency must consider 
``available information'' concerning the cumulative effects of a 
particular pesticide's residues and ``other substances'' that have a 
common mechanism of toxicity. Available information in this context 
include not only toxicity, chemistry, and exposure data, but also 
scientific policies and methodologies for understanding common 
mechanisms of toxicity and conducting cumulative risk assessments. For 
most pesticides, although, the Agency has some information in its files 
that may turn out to be helpful in eventually determining whether a 
pesticide shares a common mechanism of toxicity with any other 
substances, EPA does not at this time have the methodologies to resolve 
the complex scientific issues concerning common mechanism of toxicity 
in a meaningful way.
     In consideration of potential cumulative effects of etoxazole and 
other substances that may have a common mechanism of toxicity, there 
are currently no available data or other reliable information 
indicating that any toxic effects produced by etoxazole would be 
cumulative with those of other chemical compounds. Thus, only the 
potential risks of etoxazole have been considered in this assessment of 
aggregate exposure and effects.
     Valent will submit information for EPA to consider concerning 
potential cumulative effects of etoxazole consistent with the schedule 
established by EPA at (62 FR 42020) (Aug. 4, 1997) and other subsequent 
EPA publications pursuant to the Food Quality Protection Act.


E. Safety Determination

    1. U.S. population--i. Acute risk. The potential acute exposure 
from food to the U.S. population and various non-child/infant 
population subgroups are estimated to be 0.15 to 0.30% of the proposed 
aPAD. Exposure to potential acute residues in drinking water is 
expected to be negligible, as acute DWLOC's are substantially higher 
than modeled acute DWEC's. Based on this assessment, it can be 
concluded that, there is a reasonable certainty that no harm to the 
U.S. population or any population subgroup will result from acute 
exposure to etoxazole.
    ii. Chronic risk. The potential chronic exposure from food to the 
U.S. population and various non-child/infant population subgroups are 
estimated to be 0.24 to 1.59% of the proposed cPAD. Chronic exposure to 
potential residues in drinking water is also expected to be negligible, 
as chronic DWLOC's are substantially higher than modeled chronic 
DWEC's. Based on this assessment, it can be concluded that there is a 
reasonable certainty that no harm to the U.S. population or any 
population subgroup will result from chronic exposure to etoxazole.
    2. Infants and children--i. Safety factor for infants and children. 
In assessing the potential for additional sensitivity of infants and 
children to residues of etoxazole, FFDCA section 408 provides that EPA 
shall apply an additional margin of safety, up to ten-fold, for added 
protection for infants and children in the case of threshold effects 
unless EPA determines that a different margin of safety will be safe 
for infants and children. The toxicological data base for evaluating 
prenatal and postnatal toxicity for etoxazole is complete with respect 
to current data requirements. There are no special prenatal or 
postnatal toxicity concerns for infants and children, based on the 
results of the rat and rabbit developmental toxicity studies or the 2-
generation reproductive toxicity study in rats. Valent has concluded, 
that reliable data support use of the standard 100-fold uncertainty 
factor and that an additional uncertainty factor is not needed for 
etoxazole to be further protective of infants and children.
    ii. Acute risk. The potential acute exposure from food to infants 
and children are estimated to be 0.28 to 0.97% of the proposed aPAD. 
Exposure to potential acute residues in drinking water is expected to 
be negligible, as acute DWLOC's are substantially higher than modeled 
acute DWEC's. Based on this assessment, it can be concluded that, there 
is a reasonable certainty that

[[Page 19452]]

no harm to infants and children will result from acute exposure to 
etoxazole.
    iii. Chronic risk. The potential chronic exposure from food to 
infants and children are estimated to be 0.64 to 1.62% of the proposed 
cPAD. Chronic exposure to potential residues in drinking water is 
expected to be negligible, as chronic DWLOC's are substantially higher 
than modeled DWEC's. Based on this assessment, it can be concluded 
that, there is a reasonable certainty that no harm to infants and 
children will result from chronic exposure to etoxazole.
    3. Safety determination summary. Aggregate acute or chronic dietary 
exposure to various subpopulations of children and adults demonstrate 
acceptable risk. Acute and chronic dietary exposures to etoxazole 
occupy considerably less than 100% of the appropriate PAD. EPA 
generally has no concern for exposures below 100% of the acute and 
chronic PAD's because these represent levels at or below which daily 
aggregate dietary exposure over a lifetime will not pose appreciable 
risks to human health. Chronic and acute dietary risk to children from 
etoxazole should not be of concern. Further, etoxazole has only 
agricultural uses and no other uses, such as indoor pest control, 
homeowner or turf, that could lead to unique, enhanced exposures to 
vulnerable sub-groups of the population. It can be concluded that, 
there is a reasonable certainty that no harm will result to the U.S. 
population or to any sub-group of the U.S. population, including 
infants and children, from aggregate chronic or aggregate acute 
exposures to etoxazole residues resulting from the proposed uses.

F. International Tolerances

     Etoxazole has not been evaluated by the JMPR and there are no 
codex maximum residue limits (MRL) for etoxazole. MRL values have been 
established for etoxazole in the following countries: Turkey, Israel, 
South Africa, Japan, France, Taiwan, and Korea. The use pattern and 
MRL's are similar to those proposed for the U.S.
[FR Doc. 05-7223 Filed 4-12-05; 8:45 am]
BILLING CODE 6560-50-S